Skip to content
Adrienne Monson – Lifestyle
Author:
HELIXON
Earendil Labs Announces First Cohort Dosed in Phase I Study of Novel Biparatopic Antibody Targeting Thymic Stromal Lymphopoietin (TSLP)
May 18, 2026
Earendil Labs Announces First Patient Dosed in a Phase IIa Trial of a Half-life Extended Anti-TL1A Antibody (HXN-1001) in Patients with Ulcerative Colitis
April 2, 2026
Earendil Labs Announces $787 Million in Financing to Scale AI-Driven Biologics Discovery and Development
March 20, 2026
Earendil Labs and WuXi Biologics Enter Strategic Collaboration to Accelerate Development and Manufacturing of Bispecific/Multispecific Antibodies and ADCs
March 12, 2026